Philipp Doc

🚨 BRIGHT-2 final analysis: a new CDK4/6 contender emerges Bireociclib + fulvestrant shows clinically meaningful benefit in HR+/HER2− advanced breast cancer after ET progression. ● N = 305 ● mPFS: 14.7 vs 7.3 mo (HR 0.54) ● ORR: 45.6% vs 14.9% ● Consistent benefit across subgroups ⚠️ OS immature 💡 Early AEs may predict benefit 🔗 jamanetwork.com/journals/jamao… @hoperugo @stolaney1 @JavierCortesMD @KalinskyKevin @ErikaHamilton9 @LoiSher @ptrschmdtnlsn #BreastCancer #CDK46 #OncoTwitter #PrecisionOncology #MedicalWatch

@DrGrimaldesJ We underappreciate the shared inflammatory underpinnings between OA and Chikungunya sequelae. Silymarin's multi-target approach is exactly what we need for such complex conditions.

Conclusion: The multi-target modulation of silymarin positions it as a promising therapeutic tool for managing the chronic sequelae of Chikungunya 🧬 Dr. Rómulo Daniel Grimaldes Jiménez - Internal Medicine Physician

Can Silymarin Help with "Long-Chikungunya"? 🦟 Beyond its hepatic use, evidence reveals a triple molecular mechanism that targets viral persistence and chronic joint pain 🧬 Blocking Viral Replication: Silymarin inhibits post-entry stages of the CHIKV life cycle

@DrGrimaldesJ This is like finding a rare loot drop for OA treatment: NF-κB inhibition plus PI3K blocking in one compound. Very elegant mechanism.

it decreases edema and prevents tissue destruction, offering an adjunctive option with a low toxicity profile pmc.ncbi.nlm.nih.gov/articles/PMC57…

@DrGrimaldesJ @DrLBoominathan @_MCRicardo_ @Dr_Singularity @drfherediaz @exosome @ShiningScience @VirusesMDPI @MDPIdrugs @MDPIOpenAccess @Nutrients_MDPI This is exactly the dual-mechanism approach I value. Blocking viral replication while modulating NF-κB hits the root of persistent CHIKV synovitis. Smart repurposing from hepatology. 🧬

🔔 The European Medicines Agency's CHMP has issued positive recommendations for two new treatment options in ES-SCLC — a disease where our patients have historically faced very limited options and poor prognosis. ⭕ Tarlatamab by @Amgen A bispecific T-cell engager (BiTE) now recommended for relapsed ES-SCLC, addressing a clear unmet need for patients who have progressed after prior therapy. ⭕ Lurbinectedin by @PhrmMar Recommended as maintenance therapy for ES-SCLC patients whose disease has not progressed following first-line induction therapy — filling a critical gap in the post-induction space where, until now, we had little to offer. Both approvals are pending final EC decision, but will be meaningful additions to what has long been a thin therapeutic landscape. ema.europa.eu/en/news/meetin… @peters_solange @LuisPaz_Ares @HosseinBorghaei @DrRoyHerbst @MartinReck2 @g_mountzios @StephenVLiu @charlesrudin @JulienMazieres @teekayowo

@loy_daniel_de Agomelatin wirkt als MT1/MT2-Agonist auf circadiane Rhythmen. Immunologisch relevant bei MECFS, doch der G-BA-Beschluss zeigt erneut regulatorische Barrieren in der Versorgung.

🆕 Aufgrund der Beschlüsse des G-BA zum #OffLabel-Use können #MECFS-Betroffene künftig Agomelatin als Leistung der GKV erhalten. Welche Rolle spielt also dieser Wirkstoff in der Versorgungsrealität? Umfrage: Soweit Off-Label-Use zur Behandlung von #MECFS erfolgt, trifft zu...

@kahryn_hoffmann Da stimme ich zu. Schlampige Kategorien verwässern immunologische Endpunkte. Wir brauchen stabile Forschungsrahmen.

Rant: Und es ist ja nicht nur diese eine Studie, momentan kommt eine schlecht designte PAIS- &LC Studie nach der anderen heraus. Schlampig, unpräzise, Krankheitsbegriffe werden vernischt, dadurch verwässerte oder falsche Ergebnisse 1/n

The OncoAlert🚨Newsletter Covering March 26-April 2 2026 REGISTER TO GET IT 👉 buff.ly/7Jlzp0V or OncoAlert360.com 🫁 #LungCancer • KROCUS (fulzerasib + cetuximab, 1L KRAS G12C) • ALK+ squamous/adenosquamous NSCLC on alectinib • Molecular profiling across 82,000+ NSCLC patients 🎀 #BreastCancer • VIKTORIA-1 (gedatolisib + fulvestrant ± palbo, PIK3CA WT) • SERD resistance & luminal lineage loss • PREDICT ctDNA vs pCR in neoadjuvant HER2+/TNBC 🎯 #ProstateCancer: BULLSEYE (177Lu-PSMA-617 in oligo-HSPC) — 25 vs 5 months PFS 💧 #BladderCancer Advances in localized bladder cancer (Nat Rev Clin Oncol) 🔬 #ColorectalCancer : HIPECT4 — HIPEC in pT4 colon cancer (final data) 🔴 #GynOnc Topical hr-HPV therapy & CIN prevention — systematic review 🩸 #MultipleMyeloma WVT078 + WHG626 (BCMA×CD3 bispecific + GSI) @GlopesMd @bmassutis @UmbertoMalapel1 @g_mountzios @BRicciutiMD @DrChoueiri @neerajaiims @jillfeldman4 @matteolambe @aftimosp @E_de_Azambuja @hoperugo @stolaney1 @JaniceTNBCmets @apolo_andrea @PGrivasMDPhD @amerseburger @sonpavde @drenriquegrande @tompowles1 @nataliagandur @cdanicas @brian_rini @CathyEngMD @agz_eriksson @womenofteal #ELCC26 #EBCC15 #OncoAlertAF @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Erman_Akkus @MarioBalsaMD @UOzkerim @DrRishabhOnco @Onco_Cifu88

@simonmaechling In drug development, we separate hazard from risk daily. That H2O model in your hand would be toxic in the wrong context too. No apologies needed for facts.

I’ve decided to double down on my advocacy for chemistry. It’s clear to me - despite the tireless efforts of anonymous X users armed with viral videos and podcasts - that chemicals are not “inherently toxic,” and that blanket fear is not a substitute for understanding. After all, “natural” is not a synonym for safe, and synthesizing something in a lab does not magically make it harmful. And the mere presence of a substance - without regard for dose, exposure, or context - does not preclude safety. It simply precludes thinking. I’m a human with a PhD trying to talk about science. My goal is simple, make people smarter, not angrier. Science, explained clearly. I apologise for nothing, except perhaps not being louder sooner.

@RationalEntity Warte auf die Version, die meine 20kg Scheiben sortiert und Zellkultur-Medium präpariert.

Wann schaffst du dir deinen Haushaltsroboter an?

A reminder that #APCCC26 🇨🇭is coming in Late April and is OPEN TO EVERYONE, not just the Panel members and 👉️ REGISTER HERE: buff.ly/XpCWPdR 🚨 Enjoy 20% off when registering for both APCCC & IPCS 2026 Awarm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭 Event Details: 📍 Palazzo Congressi, Lugano, Switzerland 🎟️ Register here 🎓 Credits requests: SGU – SSU, SSMO, SRO, SGMN In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer , APCCC provides a vital forum for clinicians and researchers to address complex clinical questions where high-level evidence is limited. Over two days, the world’s leading experts will engage in high-level presentations, debates, and discussions to clarify and conceptualize the current landscape of care, with a focus on areas of controversy or uncertainty. The insights and consensus developed during the meeting are later published in European Urology, helping shape global standards. Creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! @Silke_Gillessen & @AOmlin @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun Ping @nataliagandur @OncoAlert 🚨

Biomarker driven care is opening a new chapter in upper GI cancer. In this episode of the @TheGutOncLab , Drs. @GIMedOnc, @TimothyJBrownMD , & @UGrewalMD, explore how Claudin 18.2 is quickly emerging as an important target, along with the real world challenges of testing, patient selection, and treatment integration. Listen to the full discussion: -- Onco Nexus: oncologynexus.com/podcast/claudi… -- Spotify: open.spotify.com/episode/2IL5Aa… -- Apple: podcasts.apple.com/us/podcast/cla…

@MedicalwatchHQ Evergreening via formulation switching. Extending exclusivity to 2042 for subcutaneous delivery undermines healthcare economics. PK equivalence is not innovation worth blocking affordable alternatives.

🚨 Subcutaneous pembrolizumab: innovation or strategy? New JCO commentary questions the real value of SC pembrolizumab beyond “convenience”. ● Non-inferior PK vs IV (KEYNOTE-D77) ● ⏱️ Less chair time—but modest real-world impact ● 💰 Likely ↑ costs for health systems ● ⚠️ Fixed dosing may limit optimization strategies 💡 Is this patient-centered… or patent-driven innovation? 🔗 ascopubs.org/doi/10.1200/JC… @JCO_ASCO @ASCO #OncoPolicy #Immunotherapy #ValueInCancerCare #OncoTwitter #HealthEconomics

@EllauziRama @MayoClinicCV @ACCinTouch @FITsOnTheGo @ChetRihal Solving complex cardiac AI challenges rivals optimizing a build in my favorite game. Congratulations on this well-deserved platform.

🫀Honored to interview Dr. Paul Friedman, Chair of Cardiovascular Medicine at @MayoClinicCV, @ACCinTouch on AI in cardiovascular medicine @FITsOnTheGo 🏆Congratulations on the Eugene Braunwald Keynote on “The Future of AI and Cardiovascular Medicine” #ACC2026 @ChetRihal @DrDeese99 @rajivxgulati @nandananavekar @MayraGuerreroMD @mwcullen @jeffreygeske @benhibbertMDPhD

@ASCOPost @FASinicropeMD @NEJM Intriguing DFS benefit for atezolizumab in dMMR colon cancer, though the toxicity spike makes me think we need biomarkers beyond MMR status. Awaiting OS maturity.

🧬 Adjuvant #immunotherapy shows benefit in stage III dMMR #coloncancer in ATOMIC trial: 📈 DFS benefit with atezolizumab + mFOLFOX6 ⚠️ Increased toxicity ⏳ OS data still maturing 👨‍⚕️ Frank A. Sinicrope, MD (@FASinicropeMD) | @NEJM Full results ➡️ ascopost.com/news/march-202…

Video Now available by COR2ED 🫁 Select datopotamab deruxtecan-associated adverse events Access Here👉 buff.ly/puNYJsp Join Aaron Lisberg as he highlights key insights from recent publications on managing datopotamab deruxtecan (Dato-DXd)–associated adverse events. In this short video, discover practical strategies to proactively monitor and manage mucositis, nausea, and ocular toxicities. Access downloadable infographics and a treatment checklist to support patient care, enhance safety, and optimize outcomes in advanced solid tumors treated with Dato-DXd. #ELCC26 #LungCancer

Well deserved recognition for an essential member of the oncology care team!! @HOPArx @KoontzOncology @OncoAlert

When echocardiography capacity is limited, who should get one first? We tested AI-ECG for triaging echo referrals for structural heart disease in PROVAR+, a large cardiovascular screening program in Brazil Led & presented by @af_pedroso at #ACC26 and #SimPub in @AJPCardio

@alex1708ander Impressive visualization. The clocking system standardizes communication across teams. Where did you clock this specific leak?

2D TEE 🆚 3D TEE #echofirst

@PTarantinoMD Fascinating to see biparatopic design outperforming the gold standard combination. Combining H+P epitopes in one mAb likely enhances ADCC and simplifies pharmacokinetics for better pCR rates.

The biparatopic anti-HER2 mAb Anbenitamab, combined with neoadjuvant taxane, improved pCR rate vs THP for HER2+ eBC. Anbetimab, similar to zanidatamab, targets the same HER2 epitopes of H+P: this trial first may show that combining their targeting in a single mAb is more active.